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AB-PAS Alcian blue – periodic acid Schiff 
CC3 cleaved caspase 3 
CK5 cytokeratin 5 
CK6 cytokeratin 6 
CK7 cytokeratin 7 
CyTOF time-of-flight mass cytometry 
ECM extracellular matrix 
EGFR endothelial growth factor receptor 
EMT epithelial to mesenchymal transition 
EMT-TF epithelial to mesenchymal transition transcription factor 
EMP epithelial mesenchymal plasticity 
FFPE formalin-fixed paraffin-embedded 
HE hematoxylin and eosin 
HIF hypoxia induced factor 
HRE hypoxia responsive elements 
IF immunofluorescence  
IMC imaging mass cytometry 
K8/18 keratin 8 & 18  
LGR5 leucine-rich repeat-containing G-protein coupled receptor 
LUAD adenocarcinoma 
LUSC squamous cell carcinoma 
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MET mesenchymal to endothelial transition 
MSW meter of sea water 
NGS next generation sequencing 
NSCLC non-small cell lung cancer 
p40 tumor protein p40 
p63 tumor protein p63 
PD1 programed death receptor 1 
PDL1 programmed death receptor ligand 1 
p-Tyr phosphotyrosine 
RCF relative centrifugal force 
ROI region of interest 
RT room temperature 
RTK receptor tyrosine kinase 
SCLC small cell lung cancer 
STFPC surfactant protein C 
TKI tyrosine kinase inhibitor 
TNM Tumor – Nodes - Metastasis 
TRP63 tumor protein 63 
tSNE t-distributed stochastic neighbor embedding 








Lung cancer is a leading cause of cancer-related morbidity and mortality worldwide, and also the 
cancer-form responsible for most cancer related deaths in Norway. Non-small cell lung cancer (NSCLC) 
accounts for approximately 80% of the lung cancer cases. Owing to the introduction of targeted therapies 
and immune checkpoint inhibitors (ICI), the treatment of NSCLC has changed drastically in recent 
years, in particular due to the remarkable clinical efficacy of ICI observed in a subset of patients. 
Although a minority of patients show prolonged clinical benefit of these drugs, innate and 
acquired resistance to ICI limit the clinical benefit and the complex molecular mechanisms 
mediating resistance is still poorly understood Thus, there are a need for preclinical models 
which are representative for the heterogeneity of the tumor microenvironment.  
 
3D patient organoids emerge as a unique and robust tool. This in vitro model mimics the 
biological in vivo characteristics of the primary patient tissue. Since hypoxia is pivotal for 
cancer growth and progression, we have aimed to study the effect of “the flip of the coin”, 
namely hyperoxia. Furthermore, to get a better understanding of the complex communication 
between tumor and the stroma, we combinate the single cell high dimensional analysis 
technique, imaging mass cytometry with the organoid model.  
 
The first two objectives of this thesis were to develop an organoid model from human non-
small cell lung cancer resection specimens, and to characterize the histoarchitecture and cellular 
composition of the organoids compared to the malignant tumors they derive from. Six different 
tumor resection specimens of various histological subtypes of NSCLC´s was included in the 
study. Establishment of patient derived organoids were successful for all resection specimens. 
Comparison between tumor and derived organoid tissues, and between the individual organoids 
was performed through application of various staining techniques. Additionally, preservation 
of genetic abbreviations from patient tumor, detected by next generation sequencing (NGS), 
was elucidated by antibody staining in derived organoids. We were able to confirm that the 
histological characteristics of different patient derived organoids varied from patient to patient, 
as expected due to differences in histological subtypes among the tumors. Most importantly, 
the derived organoids show similar growth characteristics and cellular composition compared 
to the tumor of origin. Also, the genetic mutations detected in the tumor of origin was shown 
to be preserved in organoid tissues. Furthermore, the IMC data show variation of protein 
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expression between the adenocarcinoma and squamous cell carcinoma organoids. The 
cytokeratin, CK7, was shown to be expressed only in the adenocarcinoma derived organoids.  
 
The final objective was to explore the effect of normobaric and hyperbaric oxygen treatment 
on cancer cell proliferation and phenotype, as well as ECM composition. Harvest of organoids 
in the elevated oxygen treatment groups was less efficient, indicating a suppressive effect of 
elevated oxygen. Reduced expression of the proliferation marker Ki67 were detected in the 
normobaric oxygen treatment group compared to control, however the hyperbaric oxygen 
treatment showed variable results. Thus, these experiments need to be repeated in order to be 
able to conclude about the efficiency of elevated oxygen therapy, but our results support further 



























1.1 Cancer and Cancer Statistics 
 
Cancer is a global problem and one of the leading causes of deaths. In 2020, the World Health 
Organization estimated that cancer caused close to 10 million annual deaths worldwide (1). 
Cancer is a huge global health problem, however low- to middle-income countries accounts for 
about 70% of cancer related deaths. Use of tobacco, intake of alcohol, unhealthy diet and 
physical inactivity are the 4 major risk factors for developing cancer, and 22% of all cancer 
deaths are due to tobacco use (1). Worldwide, cancer is expected to become the leading cause 
of death by the end of the 21st century (2). In Norway, as in many other high-income countries 
throughout the world, cancer already is the most lethal disease (3).  
 
 
Figure 1.1: Estimated age-standardized incidence and mortality worldwide in 2020 by 
WHO. Both sexes combined, and all ages are included. Data source: Globocan 2020. Graph by Global 
Cancer observatory (4) 
The best strategy to reduce cancer incidence is by reducing the risk factors mentioned above. 
Another strategy to lower the lethality rate is improved early detection, diagnosis, and onset of 
treatment, which could be achieved by raising awareness of symptoms, screening, and good 
access to medical services in general (1).  
 
 10 
1.2 Lung Cancer and its Subtypes 
 
Lung cancer accounts for nearly one quarter of all cancer related deaths. This malignancy has 
clearly the highest death rate of all cancer throughout the world due to the combination of its 
incidence and mortality rates, with an estimated survival rate of only 17.8% after 5 years. It is 
also the most common sex independent malignancy (Figure 1.1) (5, 6). 
 
Lung cancer is divided into two major types. Non-small cell lung cancer (NSCLC) is the 
dominant type of lung cancer, and it accounts for 80 – 85% of all cases of lung cancer. The 
second major type of lung cancer is small-cell lung cancer (SCLC), which constitutes the 
remaining 15 – 20% of lung cancer cases (7). SCLC has the most aggressive growth of all lung 
cancers, with a median survival time of just two to four months (8). Nevertheless, NSCLC is 
not as aggressive but due to the high incidence rate, improvement of treatment strategy as well 
as the clinical outcome is urgently needed. Due to the severity of lung cancer at large, both for 
SCLC and NSCLC it is important to search for new therapeutic strategies to improve the clinical 
outcome (7). One of the aims of the present thesis is to test a new therapeutic strategy for 
NSCLC.  
 
NSCLC is divided into three major subtypes, adenocarcinoma, squamous cell carcinoma and 
large cell anaplastic carcinoma. Adenocarcinoma accounts for approximately 40% of all lung 
cancer cases, while squamous cell carcinoma represents around 25% - 30% and large cell 
anaplastic carcinoma with roughly 10% of the total lung cancer cases (9), the rest are SCLC 
cases. The cellular origin of lung cancer is still unknown for most cases. However, 
adenocarcinomas are usually believed to origin from the distal alveolar cells located in the 
alveolar lung epithelia, while squamous cell carcinoma traditionally is thought to arise from 
cells residing in the more proximal airway tissue.  Tissue stem cells are often believed to be 
the cell of origin for malignancies due to their long life span which allows for increased 






1.3 The TNM staging of non-small cell lung cancer (NSCLC) 
 
The stage classification system of NSCLC is based on the TNM-system, developed by the 
International Association for the staging of Lung Cancer (IASLC). In the TNM-system T stands 
for tumor, N stands for nodes and M stands for metastasis. In this system, stage is defined by 
the extent of the size of the primary tumor, the extent of spread to regional lymph nodes in 
addition to metastasis to distal sites. No other factors such as the biological characterization of 
the tumor or clinically symptoms are included in this stage classification system (11). For now, 
the staging system remains the most important prognostic factor for survival rates and time, 
despite the huge efforts of research in the area of additional molecular prognostic factors. In the 
future we will most likely see the development of a system combining the TNM-system and 
biomarkers (12).   
 
The stage classification TNM system is divided into four major stages, stage I, II, III and IV as 
shown in Table 1.1. These stages are further split into individual substages. The staging system 
is rather complex, and each stage is determined by the composition of the TNM factors. In stage 
I, no spread to the lymph nodes nor distant metastasis have been detected. This means that N 
and M values equals 0, but values of T are higher than 0. For stages II and III, no metastasis 
has been detected, but most of the subtypes have spread to the lymph nodes. This means that in 
most substages N values exceeds 0, but the M value still equals 0. All cases in which there are 
metastasis, meaning that the M value exceeds 0, are classified as a stage IV malignancy, despite 
the values of T and N (12, 13).  
 
Table 1.1 NSCLC stage classification TNM system.  
Stage T (Tumor size in cm) N (Nodes) M (Distant metastasis) 
I <3 0 0 
II 3-7 >0 0 
III >7 >0 0 






1.4 Treatment of NSCLC 
 
When it comes to treatment of NSCLC patients it varies, but there are some standard 
recommendations for treatment based on the individual stages. For stage I malignancies in 
general the preferred treatment strategy is surgery. More specifically lobectomy is the 
recommended surgical procedure. Only selected patients presenting with stage I malignancies 
gets additional, or adjuvant, treatments. The recommendation for stage II malignancies is 
multidisciplinary treatment strategies, such as surgery followed by adjuvant platinum-based 
chemotherapy. Some stage II patients are candidates of chemo-radiotherapy treatments. For 
patients presenting with the more advanced stage III and IV cancers, the treatments are more 
individually tailored to the various substages and molecular features. Different 
multidisciplinary treatment strategies can include lymph node dissection, adjuvant 
chemotherapy and platinum-based chemo radiation therapy or immunotherapy with immune 
checkpoint inhibitors (14, 15). 
 
The pathologist also evaluate the invasive probability of adenocarcinomas and classify them 
into five different predominant patterns, lepidic-, papillary-, acinar-, micropapillary- and solid 
adenocarcinoma (16). Molecular evaluation of the adenocarcinomas by next generation 
sequencing (NGS) and IHC-P is also performed. Patients positive for selective mutations, such 
as EGFR deletion in chromosome 19 are candidates for targeted therapy. Tyrosine kinase 
inhibitors (TKI) like erlotinib are suited for targeting cancer cells harboring this EGFR mutation 
(17). Each molecular aberration detected of the ones that are screened is suited for different 
target therapies (18).  
 
In cases of squamous cell carcinomas on the other hand, NGS screening is not conducted. 
There are only a few target mutations in this subtype of NSCLC (19). In Norway, there are no 







1.5 The Tumor Microenvironment  
 
Tumors are present as heterogenous tissues with malignant cells surrounded by a tumor 
microenvironment. The tumor microenvironment consists of fibroblasts, endothelial-, stromal, 
and immune cells in addition to the extracellular matrix (ECM) (Figure 1.2) (20).  The ECM is 
composed mainly of proteoglycans and fibrous proteins, such as collagens, laminins, and 
fibronectins, which together provide the ECM with varied architecture as well as 
viscoelasticity. The ECM fill the majority of the interstitial space within a tissue (21). The tumor 
microenvironment is more acidic than normal tissue. The acidic conditions of the tumor 
microenvironment are due to a general increased glucose metabolism, which leads to H+ 
production and excretion. The increased glucose metabolism (glycolysis) in combination with 
poor perfusion results in a more acidic environment (pH 6.5 – 6.9). The acidic environment 
may lead to cathepsin proteinase release and activity which is believed to be involved in local 
invasion and tissue remodeling (22). Hypoxic conditions are one of the key features of the 
tumor microenvironment, described in more detail later (1.6). Within the tumor 
microenvironment there is exchange of advanced information driven by growth factors, 
cytokines, chemokines, enzymes, and proteins. It is believed that the communication between 





Figure 1.2: Illustration of the tumor microenvironment. The figure illustrates the basis structure 
of the tumor microenvironment, including extracellular matrix, and all the cellular components; fibroblasts, 




1.6 Hypoxia in Cancer 
 
Hypoxia is an important hallmark of the tumor microenvironment. Hypoxia is defined as an 
area where cells are deprived from the adequate amount of oxygen. Tumor hypoxia is 
recognized by the low levels of oxygen within the malignant tumor (0.3% - 2.1% O2 (23)) (24), 
due to uncontainable proliferation, altered metabolism and abnormal tumor vessels.  
Most solid tumors, including lung cancers, often consist of areas of acute or chronic hypoxia 
(25). Although severe and long-lasting hypoxia is toxic, many cancer cells have the ability to 
adapt to the hypoxic microenvironment, and are able to survive and proliferate despite the 
limited oxygen availability (26). 
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Conventionally, hypoxia was believed to be a limiting factor of tumor- and cancer growth, and 
this hypothesis was based on the fact that cells need oxygen for cell division. However, in the 
last decades hypoxia has been proven to be a key factor in cancer progression (27). Modern 
studies suggest that tumor hypoxia correlates with more malignant cancer cells (Figure 1.3) 
with induced cellular adaptions resulting in increased proliferation and cancer growth (15). It 
has been reported that hypoxia in tumors could result in improved oxidation and viability of 
malignant cells through induced angiogenesis, by increased glycolysis and up regulation of 
genes that are involved in cell survival and apoptosis and increased immune suppression (Figure 
1.3) (28). In addition, hypoxia has been shown to induce epithelial to mesenchymal transition 
(EMT) which may lead to more therapy resistance and invasive and metastatic phenotypes (28, 
29). Considering the latest research, hypoxia in tumor tissues can be seen as an independent 
prognostic factor and a significant risk factor of development of metastasis, in addition to 
development of treatment resistance (29).  
 
 
Figure 1.3: Tumor hypoxia results in enhanced tumor development and progression. This 
figure illustrates how hypoxia affects cancer. Hypoxia is involved in angiogenesis, immune suppression, cell 




The effects of hypoxia are mediated by hypoxia-inducible factor (HIF) transcription factors. 
HIF1 alpha is the most enriched isoform of HIF, and this transcription factor responds to 
variation in available oxygen. HIF1 alpha is stabilized under hypoxic conditions. This 
increased expression is mostly controlled by decreased proteolytic degradation. Under these 
hypoxic conditions HIF1 alpha will translocate into the nucleus to communicate with genes to 
induce transcription of genes whose promoter is under regulation of hypoxia responsive 
elements (HREs). On the other hand normoxia rest destabilize HIF1 alpha by hydroxylation 
which ultimately results in degradation (Figure 1.4) (30). High expression of HIF1 alpha is 
found in a broad range of tumors, including NSCLC, and this hypoxia biomarker is associated 





Figure 1.4: The role of HIF1 alpha in hypoxia and the degradation under normoxia. 
Representation of how HIF1 alpha enters nucleus and activate transcription, and the mechanics of the 





1.7 Epithelial to mesenchymal transition (EMT) 
 
Despite the fact that heterogeneity of the origin and complex molecular mechanisms behind the 
development of malignancies are not fully known, and despite the heterogeneity, most solid 
tumors are established in similar manners. Cancer development is defined as a multistep process 
where somatic cells are first affected by an initiating step (e.g. predisposing environmental 
changes and epigenetic events) before promoting events like genetic mutations (33). The 
outcome of both events results in genetic modification.  Accumulating somatic mutations 
mostly affects several hallmarks such as genomic instability, proliferative signaling, resisting 
of apoptosis, inflammation, angiogenesis, invasion, and metastasis (20). 
 
Epithelial to mesenchymal transition (EMT) play an important role in cancer- development and 
progression. Traditionally, EMT is described as the transition of epithelial cells to cells with 
mesenchymal phenotype in the process of embryonic development. In this process the epithelial 
cells lose their polarity and cell to cell adhesion and become a more mesenchymal like cell type. 
This feature gives the malignant cells the opportunity of metastasis through multiple steps, 
including detachment of malignant cells from the primary tumor. This leads to invasion into 
the surrounding microenvironment, invasion into blood- and lymph vessels and finally, growth 
possibilities at a secondary site (mesenchymal to epithelial transition). Typical markers for 
EMT are vimentin, E-cadherin, upregulation of SNAIL, TWIST, TGF-beta, HIF1 alpha. 
However, some of these markers get upregulated, while others are downregulated during EMT. 
Importantly, EMT is not considered as a stochastic transition from completely epithelial to 
completely mesenchymal cells, but the cells can also undergo partial EMT to obtain 
intermediate E-M states. Together with the reversed mechanism, mesenchymal to epithelial 
transition (MET), this gives rise to Epithelial mesenchymal plasticity (EMP) which contributes 
to the cells ability to undergo functional adaption to the environment (34). The complexity of 
EMP ensures the malignant cells the property of adaption to the hostile and changing 
environment (35, 36).  
 
The cancer progression could be driven by EMT-activating transcription factors (EMT-TFs). 
EMT-TF´s such as SNAIL1, SNAIL2 and TWIST1 have been proven to be partially or 
independently responsible for EMT. The EMT-TFs have a role in both cancer- progression, 
tumor growth, invasion, and metastasis. Additionally, these EMT-TFs have shown to acquire 




1.8 The role of hypoxia in EMT 
 
EMT is induced by hypoxia by HIF1alpha upregulation of the EMT-TFs which further activates 
EMT signaling pathways. The regulation is driven by the HIF´s. HIF1 alpha has been shown to 
promote EMT both trough upregulation of EMT-TFs like SNAI1- and TWIST (32). These 
mechanisms promote cancer progression and metastasis of malignant cells. HIF1 alpha is also 
correlated with the Cadherin switch (32), upregulation of N-Cadherin and downregulation of 
E-Cadherin (37), a key hallmark of EMT. Activation of AXL, a Receptor Tyrosine Kinase 
(RTK) has shown to be induced by HIF1 alpha. AXL is related to both EMT, tumor plasticity 
and drug resistance. The targeting of AXL by HIF1 alpha is regulated by the mentioned EMT-
TFs as well as other microenvironmental factors (24).  AXL are also directly regulated by 




Figure 1.5: Hypoxia induced endothelial to mesenchymal transition. This illustration shows 
how hypoxia induces both EMT and immunosuppression as well as genetic and epigenetic changes in the 
tumor microenvironment. Illustration adapted from (24).  
 
Thus, since hypoxia is pivotal for cancer growth and progression, one of the aims of this thesis 
is to evaluate the effect of elevated oxygen (“the flip of the coin”) in a patient derived three-
dimensional tumor organoid model.  
 
 
1.9 Patient derived three-dimensional organoids 
 
Patient derived organoids are three-dimensional cellular structures derived from either normal 
or tumor tissue. The stem cells have the capacity of self-forming into cellular structures 
resembling the tissue of origin (38), with both histopathology and gene mutations as the tissues 
they are derived from (32).  
 
These organoids constitute a valuable research model for therapeutic efficacy, molecular 
mechanisms of drug resistance as well as toxic side-effects (33). We therefore developed patient 





















Overall aim: Development and Characterization of an ex vivo Organotypic Non-Small 
Cell Lung Cancer Model to Study the Effect of Elevated Oxygen Treatment 
 
 
Specific Aims:  
1. Establish an organoid model from human non-small cell lung cancer resection 
specimens. 
 
2. Characterize the histoarchitecture and cellular composition of the organoids 
compared to the malignant tumors they derive from. 
 
3. Explore the effect of normobaric and hyperbaric oxygen treatment on cancer cell 















3. Methods  
 
3.1 Establishment of a patient derived Organoid Model 
 
For establishment of a patient derived lung tumor organoid model the protocol developed by 
Hans Clevers group (39) was used as a basis. We established organoids from a total of 6 patients 
Table 3.1. Out of the six tumor tissues received there were four adenocarcinomas (L1, L2, L3 
and L5) and two squamous cell carcinomas (L4 and L6). Organoids derived from the individual 
patients were cultured for a varied time, from two to fourteen weeks. Most of the derived 
organoids was cryopreserved and harvested for future use, after two to three passages. 
 
Table 3.1: Received tumor resection specimens for establishment of organoids.   
Lung 
tumors 
L1 L2  L3 L4  L5 L6 
Type LUAD Lepidic LUAD LUAD LUSC LUAD LUSC 
Table shows the six different lung tumor resection specimens received for establishment of derived 
organoids. Lung tumor 1-6 (L1-L6) and subtype of NSCLC.  Establishment of NSCLC organoid cultures 
were successful for tissue from all lung tumor tissues included. LUAD – Adenocarcinoma and LUSD – 
Squamous cell carcinoma 
 
 
For the establishment of organoids, tumor tissue specimen was received directly from the 
operating theatre at Haukeland Universitets Sykehus, or cryopreserved organoids received from 
Laurence Hoareau (researcher, Klinisk Institutt UiB). Both received tumor tissue and 
cryopreserved organoid were of NSCLC origin. All tumor tissues received was approved with 
informed consent with the individual patients, and all necessary documents was signed, and the 
study approved by the local ethical committee (REK Vest: #66610). The tumor tissue was 
brought to the cell lab where it was processed as described in Figure 4.1. Shortly described, the 
tumor resection specimen received directly from the operating theatre was minced into very 
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small pieces by scalpel, washed, digested in collagenase in an orbital shaker, strained and finally 




Figure 4.1: Establishment of patient derived lung tumor organoids workflow. This figure 
illustrates the roughly workflow of the establishment protocol used for the organoids. A tumor resection 
specimen received directly from the operating theatre was minced into very small pieces by scalpel, washed, 
digested in collagenase in an orbital shaker, strained and finally seeded in Matrigel-drops and cultured in 
defined serum-free medium.  Illustration made in Biorender.  
 
 
3.1.1 Protocol for establishment of patient-derived airway organoids 
 
The organoids from lung patient number 1 (L1) were established from cryopreserved lung 
organoids of non-small cell lung cancer tissue (NSCLC). Cryopreserved organoids were thawed 
on ice and washed with AdDF+++ (Advanced DMEM/F12 with 1% GlutaMax, 10 mM HEPES 
and 1% Penicillin Streptomycin), and then spun down for 5 minutes at 400 RCF (relative 
centrifugal force). Washed organoids were resuspended in Matrigel (Corning, 354230, Bedford, 
MA, United States), 50 µL of Matrigel/well of organoid seeding. The resuspended organoids 
were seeded in each well, in pre warmed 24-well plates (Sarstedt, 83.3922, Newton, NC, United 
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States), before a 30-minute inverted incubation (upside down incubation of plate) at 37°C 5% 
O2 and 5% CO2, to ensure that the organoid do not sink to the bottom of the plate. Each of the 
wells will then establish a Matrigel dome. Organoids were cultured in two different conditions: 
differentiation medium with alveolar adapted conditions (Table1: Alveolar medium- as is, but 
with 3 µM of CHIR99021(GSK3 inhibitor/Wnt activator added), or with bronchiolar adapted 
conditions (Table1: Bronchiolar medium- as is). At the top of each of the Matrigel domes, 600 
µL of the bronchiolar and/or alveolar differentiated medium was added. The organoid medium 
was changed twice a week and the organoids where passaged every other week.  
 
The organoids from patient number 2 to 6 (L2 – L6) were established from patient lung tumor 
tissue. The resected tumor specimen was digested in Bronchiolar medium containing 1-2 
mg/mL collagenase III (Worthington, #LS004182, Lakewood, NJ, United States). The seeding 
procedure was conducted as explained above for patient 1.  
 
Table 1: Organoid medium as fundament medium.  
Media component 





concentration activation block 
R-Spondin 1 Wnt/ -catenin signaling Peprotech 120-38 500 ng/ml 
FGF 7 FGFR2b signaling Peprotech 100-19 25 ng/ml 
FGF 10 FGFR2b signaling Peprotech 100-26 100 ng/ml 
Noggin TGF-  signaling Peprotech 120-10C 100 ng/ml 
A83-01 TGF-  signaling Tocris 2939 500 nM 
Y-27632 ROCK signaling Abmole Y-27632 5  M 
SB202190 p38 MAPK signaling Sigma S7067 500 nM 
B27 supplement Insulin signaling Gibco 17504-44 1x 
N-Acetylcysteine Antioxidant Sigma A9165-5g 1.25 mM 
Nicotinamide Co-enzyme precursor Sigma N0636 5 mM 
GlutaMax 100x Nutrient Invitrogen 12634-034 1x 
HEPES Buffer Invitrogen 15630-056 10 mM 
Penicillin / 
Streptomycin 
Antibiotics Invitrogen 15140-122 
100 U/ml 
100  g/ml 
Amphotericin Antibiotic/antimycotic Sigma A2942  2,5 µg/mL 
Advanced DMEM/F12 Base medium Invitrogen 12634-034 1x 
Bronchiolar differentiation medium as in table. Alveolar differentiation medium as in table shown with 
added CHIR99021 (GSK3 inhibitor/Wnt activator), final concentration 3 µM. 
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3.1.2 Passage and expanding of airway organoids 
 
Dense organoids for expanding were resuspended in cold AdDF+++ and mechanically shared by 
using a pipette (pipetting up and down to Matrigel is dissolved) followed by centrifugation for 
5 minutes at 400 RCF. Organoids were then resuspended in TrypLE (Gibco, 12604013, Grand 
Island, NY, United States) for 1-5 minutes before the addition of 10 mL AdDF+++ for 
inactivation of TrypLE. A second spin down was executed, and the shared organoids were 
resuspended in Matrigel and reseeded to 24-well plates at a 1:6 ratio. Finally, appropriate 
medium (bronchiolar- or alveolar- medium) was added to the respectively organoids. For the 
less dense organoids or organoids for further experiments, the TrypLE step was skipped, and 
these organoids were reseeded in a 1:3 ratio.  
 
 
3.1.3 Cryopreservation and fixation of airway organoids 
 
For cryopreservation, the organoids were resuspended in wash medium (DMEM/F12 with 1% 
BSA cell culture grade) and centrifuged for 5 minutes at 400 RCF before the supernatant was 
discarded and the organoid pellet was resuspended in freeze medium (Bambanker Direct, 
BBD01, Düren, Germany). Harvesting of organoids was performed by resuspending in wash 
medium, spinning down at 400 RCF for 5 minutes, and washing organoids in PBS. Finally, 
organoids for FFPE embedding where fixed in 3,7% formalin.  
 
 
3.1.4 Cell cultures 
 
The lung cells HCC827 (ATCC, CRL-2868, Manassas, VA, United States) and A549 (ATCC, 
CCL-185) were used to generate control spheroids. The spheroids were used as control in the 
treatment of organoids, by comparing the impact of O2 treatment between spheroids and 
organoids. HCC827 cells were cultured in RPMI 1640 medium (Sigma- Aldrich, R8758, Saint 
Louis, MO, United States) and A549 cells were cultured in DMEM F-12 Ham (Sigma Aldrich, 
D8062). Both mediums were supplemented with 2% L-Glutamine (Sigma Aldrich, #G-0781), 
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5% foetal bovine serum (FBS) (Gibco) and 1x concentration of 100 µg/μl streptomycin (Sigma 
Aldrich, Penicillin-Streptomycin, #P-0781).  
 
3.1.5 Passaging of cells 
 
Cells were split twice a week by first removing the medium and rinsing with PBS followed by 
the addition of 3 mL of trypsin and incubation at 37°C until the cells detached from the culture 
plate of the T-175 cell culture flask (Sarstedt, 83.3912.002). Cells were transferred to falcon 
tubes and spined down at 300 RCF for 5 minutes. Furthermore, the cells were resuspended in 
RPMI 1640 (HCC827) or DMEM F-12 Ham (A549) medium and seeded in new flasks.  
 
 
3.1.6 Establishment of spheroids 
 
Spheroids for IMC panel optimalisation were established from both HCC827 parental- and 
A549 cells. After trypsinization and collection of cells at centrifugation at 300 RCF for 5 
minutes, the cells were resuspended in adequate medium (RPMI 1640 for HCC827 parental- 
and DMEM F-12 Ham for A549 cells) and counted by using Bürker counting chamber (Brand, 
718920, Wertheim, Germany). To develop each spheroid, nine thousand cells in 100 µL of 
culture medium was seeded into each well of a round bottom ultra-low attachment 96 well-
plate (Corning, 7007). Furthermore, the plate was centrifuged at 1000 RCF for 20 minutes. 




3.2 Characterization of organoids  
 
3.2.1 Paraffin embedding of formalin fixed organoids 
 
Harvested organoids were fixed in 3.7% formalin for 24 hours on a rotator (Stuart, SB3, Essex, 
UK) at room temperature. Organoids were then washed with PBS and stained with methylene 
green (40) for 5 minutes, before a second PBS wash. Further, organoids were resuspended in 
100 µL of pre-warmed 1.5% agarose (Sigma, A9045) dissolved in TBS (Biorad, #1706435), 
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spun down at 100 RCF for 1 minute and incubated at 4°C for 30 minutes for solidification. The 
solid agarose pellet with organoids was transferred to a cell safe biopsy capsule (CellPath, EBE-
0201-02A, UK and Simport, M498-2, Canada) and stored in 70% ethanol until paraffin 
embedding according to standard protocols. The paraffin embedded organoid specimens were 
sectioned by a microtome into 5 µm sections at the MIC core facility and collected at 
SuperFrost+ slides (10149870, Thermo Scientific). Hematoxylin and Eosin (HE) staining of 
each sample was performed. Both sectioning and staining procedures were performed by the 
Molecular Imaging Centre at the University of Bergen.  
 
 
3.2.2 Immunofluorescent (IF) for confocal microscopy 
 
Formalin fixed paraffin embedded slides were pencil labeled and deparaffinized from xylene 
(first for 5 minutes, then an additionally 10 minutes) trough decreasing levels of ethanol (100% 
x2, 96% x2, 70% x1 and 50% x1) followed by rehydration in H2O. Performed for 5 minutes at 
each step. Heat-induced retrieval was performed in a decloaking chamber (Decloaking 
Chamber NxGen, Biocare Medical). The decloaking chamber was set to 95°C. The heat-
induced epitope retrieval was conducted in DAKO Target Retrieval Solution (Dako, s1699) for 
25 minutes. After the retrieval the chamber was cooled down to 80°C before the container with 
buffer and slides was incubated in room temperature for 20 minutes to cool down. Further, 
slides were washed in H2O 3 x 5 minutes. Remaining water was wiped off and the tissue was 
encircled with a hydrophobic pen (DAKO, S2002, Glostrup, Denmark). Blocking buffer (TBST 
with 1% BSA) was added to the tissue for 30 minutes. Subsequently, the primary antibody 
incubation was conducted in 4°C, overnight. Primary antibody solution contains antibodies 










Table 2: IF Primary antibodies. Primary antibodies used for IF.  
Target Host animal Clone Suplier Cat#  Dilution  Comments 
Alpha Tubulin  Mouse DM1A Sigma T6199 1:200 Good 
Ki67 Rabbit poly Abcam ab15580 1:600 Good 
CC3 Rabbit poly CST 9661S 1:100 Some signal 
VEGFA Rabbit EP1215Y Abcam ab210073 1:100 Good 
HIF-1alpha Rabbit EP1176Y Abcam ab185238 1:100 Good 
panKeratin Mouse AE1/AE3 Dako M3515 1:200 Good 
AXL Mouse 108724 CST MAB154 1:100 Good 
 
 The next day the slides were moved out of the cold room. After 30 minutes calibration at room 
temperature, the slides where washed 3x5 minutes with PBS containing 0.1% Triton X-100 
(Sigma, T8787), followed by secondary antibody in a 1:200 dilution incubation for 1 hour in 
room temperature. The secondary antibody solution consists of antibodies dissolved in blocking 
buffer (Table 3). 
 
Table 3: IF Secondary Antibodies 
Host Target Conjugate Vendor Cat# Dilution 
Goat Rabbit AF 647 Invitrogen A21244 1:200 
Goat Mouse AF 546 Invitrogen A11030 1:200 
 
The secondary antibodies were spun down before use, two different secondary antibodies were 
used to match the primary antibodies. After the secondary antibody incubation, the slides where 
washed 3x5 minutes in PBS. Finally, slides where mounted with Prolong DAPI Diamond 
(Thermo Fisher Scientific, P36962) and incubated over night at room temperature and moved 
to 4°C the next day. 
 
 
3.2.3 Imaging by Olympus VS120 slide scanner 
 
Samples with Hematoxylin and Eosin (HE) stains, and samples stained with fluorescent 
secondary antibodies were imaged and scanned using an Olympus VS120 slide scanner. For 
HE stained samples the Brightfield – Expert mode was used. Initially the samples were scanned 
with the overview option (4X). Followed by the overview scan, ROIs (region of interest) were 
selected and scanned using 20X objective. The ROIs were extracted and saved as JPEG (digital 
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image format). Samples stained with fluorescent secondary antibodies were imaged and 
scanned in the Fluorescent – Expert mode. Brightfield option was used in overview scan. After 
the overview scan, ROIs were selected and scanned with 20X objective with appropriate lasers.  
The laser intensity of each channel was adjusted against a negative control, and the laser 
intensity remained constant for the entire sample set. The ROIs (digital images) were extracted 
and saved as both JPEG and TIFF formats.  
 
 
3.2.4 Quantification of Ki67 from IF data 
 
For the immunofluorescent stained samples with Ki67 antibody (proliferation marker), mitotic 
index was evaluated in CellProfiler software (Broad Institute Inc., v.4.0.4). Firstly, TIFF files 
exported from Olympus VS120 was uploaded to Fiji (Fiji contributors) (41), where the TIFF 
files were split to the separate channels of DAPI (Nuclei) and Ki67. The sets of images were 
then uploaded into CellProfiler (42) and listed into two separate lists in the NamesAndTypes 
module. The DAPI images were scaled for visibility into a “DNA” image, while the Ki67 
images were scaled for visibility into a “Ki67” image. The nuclei were identified by the 
IdentifyPrimaryObjects module, “DNA” image was used as input. Ki67 positive nuclei were 
identified in the same module using “Ki67” as input image. These two image sets were related 
in the RelateObjects module, with nuclei as parent- and Ki67 as child- object. After the two 
image sets were related, “Nuclei” was filtered by “Ki67” in the FilterObjects module.  By 
adding the ClassifyObject- and CalculateMath- modules the software calculated the percentage 











3.3 Elevated oxygen treatment  
 
3.3.1 Normobaric and hyperbaric oxygen treatment of organoids 
 
Organoids derived from lung tumor patient 1, 2 and 3, were exposed to both control and 
elevated oxygen treatment.  
 
Thus, three sperate 24-well plates with organoids, passage 1 and 2, were seeded. One control 
plate with 3 wells of tumor alveolar organoid and 3 wells with tumor bronchiolar organoids. 
The control was untreated and kept in a humidified incubator at 37°C with 5% CO2 and 5% O2 
(Panasonic, MCO-170MUV-PE). The second plate was treated with 100% O2 for 90 minutes 
every day for consecutive 5 days at normal atmospheric pressure (1 bar). The last plate was 
treated in 100% O2 at elevated ambient pressure (2.4 bar, 14 msw (meters of sea water)) at the 
same interval as the 1 bar plate. An OXYCOM 250 ARC (Hypcom) oxygen chamber was used 
to conduct both the normobaric and hyperbaric treatment. The pressure was carefully increased 
and decreased over a time interval of 10 minutes between 1 bar and 2.4 bar before and after the 
90-minute interval, to not risk any unnecessary harm to the organoids by the increasing 
pressure. Every 30 minute of the hyperbaric treatment, a O2 flush was conducted to keep the O2 
level at 100% throughout. Both the normobaric oxygen treatment and the hyperbaric oxygen 
was conducted in the oxygen chamber with the temperature of an average of 37°C. In-between 
the hyperoxic treatments, these organoids were kept in the same condition as the control plate.  
 
IF staining was performed for investigation of treatment effects. The staining with the 
proliferation marker Ki67 was performed two times for each treatment group. Representative 
areas of expression for the control groups were chosen, however, for the treatment groups all 








3.3.2 Temperature calibration of oxygen chamber 
 
The temperature inside the OXYCOM 250 ARC chamber during the treatment sessions was 
achieved by heating the chamber with a heat gun before the treatment, in addition to a hot 
water bag kept inside the chamber throughout the experiment. The temperature of the 
chamber was monitored by a thermometer. The temperature was held between 39°C and 
35°C. This procedure was elucidated through pilot studies.  
 
 
3.4 Imaging Mass Cytometry  
 
3.4.1 Immunostaining for Hyperion (FFPE staining workflow) 
 
Formalin fixed paraffin embedded control samples or organoid tissue specimens on 
Superfrost plus microscope slides (Thermo Fisher Scientific,10149870) were labeled with 
pencil before deparaffinization in xylene (2x10 minutes), decreasing levels of ethanol (100% 
x2, 96% x2, 70% x1 and 50% x1) and finally rehydration in H2O, for 5 minutes each. Heat 
induced target retrieval was achieved in a decloaking chamber. The decloaking chamber was 
runed at 95°C for 30 minutes. The heat-induced epitope retrieval was conducted in DAKO 
Target Retrieval Solution (Dako, s1699). At the end of the program, the decloaking chamber 
was cooled down to 80°C followed by a 20-minute incubation at room temperature to allow 
the slides to cool down. Further, the slides were washed 10 minutes in milliQ water, followed 
by a 10-minute wash with PBS (Sigma, P1379) with 0.1% Tween-20 (Sigma, D8537). Both 
washing steps were executed with careful shaking to achieve reduction of unspecific binding. 
The tissue on the slides were encircled with hydrophobic pen (DAKO, S2002). Blocking 
buffer (PBS w/5% BSA and 0.1% Tween-20) was added to the tissue for incubation for 45 
minutes at room temperature in a hydration chamber. Immediately after the blocking step, the 
primary antibody mix (Table 4 and 5) was added, followed by incubation at 4°C, overnight. 
Primary antibody solution contains antibodies diluted in 0.5% BSA in PBS. The primary 
antibody mix was centrifuged for 5 minutes at 1000G in 4°C. The following day, the slides 
were washed for 2x8 minutes in PBS w/0.1% Tween-20 followed by 2x8 minute wash in 
PBS. Both of these washing steps were performed with gentle agitation. Subsequently, the 
tissue was stained with 250 µM Intercalator-Ir (Fluidigm, 201192B) in PBS for 30 minutes in 
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room temperature, followed by one wash with PBS and one with milliQ water, each for 5 
minutes. The slides were dried without direct contact between tissue paper and sample. The 
fully stained slides were stored in a at 4°C inside a container to avoid dust. In this protocol, all 
solutions were made by using MilliQ water and kept in plastic bottles to avoid contaminations 
of heavy metals. 
 
Table 4: Organoid Panel 
Element Mass Target Clone Vendor Cat# Dilution 
Pr 141 K5/6 D5/16B4 Millipore MAB1620  1:25 
Nd 142 EGFR D38B1 Fluidigm 3142013D  1:100 
Nd 143 Vimentin D21H3 Fluidigm 3143027D  1:100 
Nd 144 p-Tyr p-Tyr-100 Fluidigm 3144024D  1:50  
Nd 145 Laminin poly Thermo Fisher PA1-6730  1:800 
Nd 146 TNF-alfa MAb11 Fluidigm 3146010B  1:50 
Nd 148 pan-keratin C11 Fluidigm 3148022D  1:100 
Sm 149 STFPC poly Thermo Fisher PA5-76631  1:25 
Eu 151 TRP63 poly Abcam ab53039  1:50 
Eu 153 AXL  A431 R&D Systems AF154  1:500 
Sm 154 HIF1a EP1176Y Abcam ab185238  1:25 
Gd 158 E-cadherin 2,40E+11 Fluidigm 3158029D  1:50 
Gd 160 VEGFA EP1215Y Abcam ab210073  1:25 
Dy 162 LGR5 poly Abcam ab75732  1:50 
Dy 163 TGFbeta TW4-6H10 Fluidigm 3163010B  1:50 
Dy 164 CK7 RCK105 Fluidigm 3164028D  1:100 
Ho 165 b-catenin D13A1 Fluidigm 3165032D  1:200 
Er 166 AXL  7e10 Thermo Fisher MA5-15504  1:250 
Er 168 ki67 B56 Fluidigm 3168022D  1:250 
Tm 169 Collagen type I poly Fluidigm 3169023D  1:50 
Yb 171 Histone H3 D1H2 Fluidigm 3171022D 1:1000 
Yb 172 Cleaved Caspase3 5A1E Fluidigm 3172027D  1:25 
Yb 174 K8/18 C51 Fluidigm 3174014A  1:50 







Table 5: Organoid Immune Cell Panel 
Element Mass Target Clone Vendor Cat# Dilution 
Pr 141 K5/6 D5/16B4 Millipore MAB1620  1:25 
Nd 142 EGFR D38B1 Fluidigm 3142013D  1:100 
Nd 143 Vimentin D21H3 Fluidigm 3143027D  1:100 
Nd 144 p-Tyr p-Tyr-100 Fluidigm 3144024D  1:50 
Nd 145 Laminin poly Thermo Fisher PA1-6730  1:800 
Nd 146 TNF-alfa MAb11 Fluidigm 3146010B  1:50 
Nd 148 pan-keratin C11 Fluidigm 3148022D  1:100 
Sm 149 STFPC poly Thermo Fisher PA5-76631  1:25 
Nd 150 PD-L1 E1L3N Fluidigm 3150031D  1:25 
Eu 151 TRP63 poly Abcam ab53039  1:50 
Eu 153 AXL  A431 R&D Systems AF154  1:500 
Sm 154 HIF1a EP1176Y Abcam ab185238  1:25 
Gd 155 FoxP3 236A/E7 Fluidigm 3155016D  1:25 
Gd 156 CD4 EPR6855 Fluidigm 3156033D  1:100 
Gd 158 E-cadherin 24e10 Fluidigm 3158029D  1:50 
Tb 159 CD68 KP1 Fluidigm 3159035D  1:50 
Gd 160 VEGFA EP1215Y Abcam ab210073  1:25 
Dy 161 CD20 H1 Fluidigm 3161029D  1:50 
Dy 162 CD8a C8/144B Fluidigm 3162036D  1:50 
Dy 163 TGFbeta TW4-6H10 Fluidigm 3163010B  1:50 
Dy 164 CK7 RCK105 Fluidigm 3164028D  1:100 
Ho 165 PD-1 EPR4877(2) Fluidigm 3165039D  1:25 
Er 166 AXL  7e10 Thermo Fisher MA5-15504  1:250 
Er 167 Granzyme B EPR20129-217 Fluidigm 3167021D  1:200 
Er 168 ki67 B56 Fluidigm 3168022D  1:250 
Tm 169 Collagen type I poly Fluidigm 3169023D  1:50 
Er 170 CD3 poly Fluidigm 3170022D  1:50 
Yb 171 Histone H3 D1H2 Fluidigm 3171022D  1:1000 
Yb 172 Cleaved Caspase3 5A1E Fluidigm 3172027D  1:25 
Yb 173 CD45RO UCHL1 Fluidigm 3173016D  1:50 
Yb 174 K8/18 C51 Fluidigm 3174014A  1:50 





3.4.2 MaxPar Antibody Labeling 
 
Some of the antibodies for Hyperion was conjugated in-house using the Maxpar X8 Antibody 
Labeling Kit (201300, Fluidigm). The protocol included in the kit was used. The kit contains 
polymers, loading buffer (L-buffer), reduction buffer (R-buffer), conjugation buffer (C-buffer), 
and wash buffer (W-buffer). If not otherwise mentioned, all of the centrifugation steps were 
performed at 12,000 RCF at RT and spin columns was discarded at each of the necessary steps. 
MaxPar X8 polymer was thawed to RT and dissolved in 95 µL of L-buffer with 5 µL of the 
specific lanthanide (heavy metal) ion solution followed by 40 min incubation at 37°C in water 
bath. Concentration of antibodies to be conjugated was measured on a Nanodrop 2000 
spectrophotometer (Thermo Scientific). Calculation of antibody equivalent to 100 µg was 
added to a 50 kDa filter (MilliporeSigma, UFC505008, Saint-Louis, MO, USA) before the total 
volume was adjusted to 400 µL with R-buffer and spun down for 10 minutes.  The antibody 
was reduced by adding 100 µL of 4 mM TCEP (MilliporeSigma, 646547) in R-buffer and 
incubated for 30 minutes at 37°C. The antibody was then washed by addition of 300 µL C-
buffer, spun down for 10 minutes, washed again with 400 µL C-buffer and spun down for 10 
minutes. The metal-loaded polymer was transferred to a 3 kDa filter (MilliporeSigma, 
UFC500308) along with 200 µL L-buffer and spun down for 25 minutes, followed by an 
additional wash by 400 µL of C-buffer, then spun down for 30 minutes. Antibody reduction 
was quenched by adding 300 µL of C-buffer and spun down for 10 minutes, followed by a 
washing step by addition 400 µL C-buffer and spun down for 10 minutes. The metal loaded 
polymer was resuspended in 80 µL C-buffer and transferred to the 50 kDa filter with the 
reduced antibody and incubated at 37°C in water bath for 90 minutes to conjugate the antibody. 
The conjugation was followed by a washing step with the addition of 200 µL W-buffer and 
spun down for 10 minutes, continued by 3 additional washing steps with 400 µL of W-buffer 
and spun down for 10 minutes each. The conjugated and purified antibody was resuspended in 
10 µL of W-buffer and measured by the Nanodrop in order to calculate the volume of antibody 
stabilizer (CANDOR, Bioscience) needed to elute the antibody at a concentration of 500 
µL/mL. After removing the W-buffer by spinning down for 10 minutes the calculated volume 
for antibody stabilizer was added to the filter before inversion of the filter in a new collection 
tube. The antibody was collected by centrifugation for 2 minutes at 1000 RCF. The conjugated 




3.4.3 Hyperion setup and operation 
 
The initially setup of the Hyperion (Hyperion Imaging System, Fluidigm) was performed by 
the Flow Cytometry Core Facility at UiB. A smartphone was used to image the sample slide. 
The image was uploaded into the HTI module in the Hyperion System, where the slide was 
loaded into the sample stage. Panoramas were made based on the tissue location on the image 
scan and potentially xy offsets from image to the actual sample was taken into account at this 
stage. Calibration of the laser intensity was performed by laser ablating non-relevant areas of 
the sample with different intensities. Optimal laser intensity was chosen such that the sample 
was ablated, but the SuperFrost+ was not burned. Following the calibration of the intensity, 
ROIs were selected from the panorama image. Acquisition template including all metals in used 
panel with corresponding markers was selected to all the ROIs. In addition, the desired laser 
intensity and ablation frequency (200Hz, standard frequency) was assigned to the ROIs. Finally, 
the sample ROIs were ablated, and multiplexed images were created and exported as a .mcd 
file. The .mcd files are datafiles which contains all valuable data from the IMC-experiment.  
 
 
3.4.4 Hyperion data analysis pipeline 
 
Exported .mcd file was opened in MCD Viewer software (Fluidigm, v7.0), or histoCAT++ 
(Bodenmiller Lab) was used as a substitute software for Mac users, where the staining quality 
was evaluated for each of the markers used in the stain protocol, in all the different ROIs and 
tissue types. Quality evaluation was performed subjectively based on the signal intensity (auto 
threshold max), from spillover from neighbor channels and expected staining patterns. Based 
on the evaluation, images of the working markers were exported as .omne.tiff images for further 
analysis. For segmentation, the folder of exported images was subsequently uploaded into 
CellProfiler software (Broad Institute Inc., v.4.0.4) (link to pipeline in appendix). Image masks 
were made based on the intensity of the two Iridium DNA intercalator isotopes, in addition to 
the Histone H3 antibody stain. The two Iridium isotopes were scaled for visibility into a “DNA” 
image. Nuclei were identified using the IdentifyPrimaryObjects module, “DNA” image was 
used as input. The cells were then identified by using IdentifySecondaryObjects module with a 
1-pixel expansion rate from the nucleus, by using the IdentifyPrimaryObjects as input object. 
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The cytoplasm was identified by using the IdentifyTertiaryObjects module using both 
IdentifyPrimaryObjects and IdentifySecondaryObjects as input objects, where cytoplasm 
equals the larger object (IdentifySecondaryObjects) subtracted by the smaller object 
(IdentifyPrimaryObjects). The nuclei, cell and cytoplasm objects were converted into the final 
image masks (unit16 color format). Cell masks were saved in the same folder as the original 
.omne.tiff files exported from MCD viewer. Each ROI of the respectively experiments were 
exported into histoCAT (Bodenmiller Lab, v1.76) in their original folders. First, phenograph 
clustering was performed. The clusters were made by selecting samples of interest, as well as 
markers of interest. We used CK7, K8/18, E-cadherin, vimentin, TRP63, betaCatenin and 
panActin for the clustering. A heatmap was generated to visualize the relative expression of the 
markers of interest in the different phenograph clusters. We further applied the t-distributed 
stochastic neighbor embedding (t-SNE) algorithm using the same markers as selected for the 
phonograph clustering. For visualization of the tSNE, the samples of interest were selected, and 
the two tSNE axes were selected in the channel’s menu, phenograph option were selected in 























4.1 Development of a human airway organoid model 
 
The protocol by Sachs et al. (39) was used as a base of the establishment of the patient derived 
organoid protocol in this thesis. The protocol gave a 100% success rate of establishment of 
organoids (Figure 4.1). From all these resection specimens, the establishment of NSCLC 
derived organoids were successful. Furthermore, establishment of organoids following 
cryopreservation was also successful. 
 
Both establishment of tumor organoids cultured in alveolar- and bronchiolar differentiation 
medium was successful. L1, L2 and L3 were cultured in both differentiation mediums, while 
L4, L5 and L6 were cultured only in bronchiolar differentiation medium. Typically, better 
growth of organoids was observed in the bronchiolar differentiation medium organoids 
compared to the alveolar differentiation medium (data not shown).  
 
The patient derived organoids were successfully cultured for up to 7 passages, or around 14 
weeks in total (data not shown).  
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Figure 4.1: Established patient derived organoids. Successfully established patient derived 
organoids in culture. a) Alveolar differentiated organoid derived from L1. b) Bronchiolar differentiated 
organoid derived from L1. c) Alveolar differentiated organoid derived from L2. d) Bronchiolar differentiated 
organoid derived from L2. e) Alveolar differentiated organoid derived from L3. f) Bronchiolar differentiated 
organoid derived from L3. g) Bronchiolar differentiated organoid derived from L4. h) Bronchiolar 
differentiated organoid derived from L5. i) Bronchiolar differentiated organoid derived from L6. Scalebar 








4.2 Characterization of organoids compared to tumor of origin.  
 
Characterization of organoids compared to NSCLC tumors they derive from were performed 
under supervision of pathologist Dr. Maria Ramnefjell, at Department of Pathology, Haukeland 
University Hospital. In addition, Next-generation sequencing (NGS) data from the 
adenocarcinomas were received. The histological comparison was mainly performed by 
comparing Hematoxylin and Eosin (HE) stained sections and Alcian blue – Periodic Acid Schiff 
(AB-PAS) histochemistry stained sections of both organoids and lung tumor tissue of the 
patient they derived from. Additionally, characterization of the different organoid cultures was 
performed by immunofluorescence (IF) staining with the proliferation marker Ki67 and 
ultimately with a panel of isotope labelled antibodies by imaging mass cytometry (IMC). 
 
 
4.2.1 Characterization of patient lung tumor 1 and patient derived organoids 
 
The first patient lung tumor (L1) specimens received was an adenocarcinoma. Initially HE 
stains of patient tumor and patient derived organoids were used for comparison and 
characterization (Figure 4.2). L1 is characterized as a well differentiated adenocarcinoma 
displaying acinar growth patterns. The tumor tissue is hard to separate from the benign lung 
tissue. The most prominent feature of patient specimen is desmoplastic stroma. The NGS of the 
patient tumor was negative for the tested gene mutations (PIK3CA, BRAF, EGFR, NRAS and 
KRAS). The patient derived organoids display similar characteristics to the patient tumor tissue 




Figure 4.2: Hematoxylin and eosin (HE) stain of patient lung tumor 1 and patient derived 
organoids. a) HE-stain of patient lung tumor 1. b) HE-stain of patient lung tumor 1, zoomed insert.  c) HE-
stain of derived organoids from patient lung tumor 1. d) HE-stain of derived organoids from patient lung 
tumor 1, zoomed insert. Scalebar 100 µm (a and c). Scalebar 50 µm (b and d) 
 
Patient derived organoids derived from L1 display mainly circular/oval structural growth 
patterns. Most of the organoids have a hollow central lumen with layers of cells lining the outer 
edges of the organoid structures as seen in Figure 4.2C and D. The organoids were mostly 
around 100-200 µm in diameter. Furthermore, the AB-PAS histochemistry which detects mucin 
revealed that the organoids produce mucin and that the hollow core is mostly positive for mucin 




Figure 4.3: Patient derived lung tumor organoids in culture and with the mucin stain AB-
PAS. a) Derived organoids from lung tumor patient 1 in culture. b) AB-PAS stain of derived organoids from 
lung tumor patient 1. c) AB-PAS stain of derived organoids from lung tumor patient 1, zoomed insert. a) and 
b) scalebar 100 µm, c) scalebar 50 µm. 
 
 
4.2.2 Characterization of patient lung tumor 2 and patient derived organoids  
 
The second patient lung tumor (L2) received was a lepidic adenocarcinoma. Initially HE- stain 
of both lung tumor and patient derived organoids was used for comparison and characterization 
(Figure 4.4). L2 is a lepidic predominant adenocarcinoma, the most prominent feature of patient 
tumor is Pneumocytic-type malignant cells. The malignant cells grow only along normal lung 
structures such as alveoli, as seen in Figure 4.4. Low cell division rates are typically observed 
in the lepidic adenocarcinomas. The malignant cells are hard to detect. The NGS results for the 
patient tumor were negative for all tested mutations. Thus, the organoids were difficult to 
culture over a long period of time, and they grew slower for each passage. Subsequently, the 




Figure 4.4: Hematoxylin and eosin (HE) stain of patient lung tumor 2 and patient derived 
organoids. a) HE-stain of patient lung tumor 2. b) HE-stain of patient lung tumor 2, zoomed insert.  c) HE-
stain of derived organoids from patient lung tumor 2. d) HE-stain of derived organoids from patient lung 
tumor 2, zoomed insert. Scalebar 100 µm (a and c). Scalebar 50 µm (b and d) 
 
Patient derived organoids from L2 grew in a variation between compact organoids and hollow 
organoids, and some of the organoids had smaller vacuoles as seen in Figure 4.5. The 
bronchiolar differentiated organoids died after the first passage. The organoids were typically 
50-150 µm in diameter. Subsequently, the AB-PAS stain shows that the organoids have 





Figure 4.5: Patient derived lung tumor organoids in culture and with the mucin stain AB-
PAS. a) Derived organoids from lung tumor patient 2 in culture. b) AB-PAS stain of derived organoids from 
lung tumor patient 2. c) AB-PAS stain of derived organoids from lung tumor patient 2, zoomed insert. a) and 
b) scalebar 100 µm, c) scalebar 50 µm. 
 
 
4.2.3 Characterization of patient lung tumor 3 and patient derived organoids  
 
The third patient lung tumor (L3) received was an adenocarcinoma. The initial HE-stain of 
patient tumor and the derived organoids used for comparison and characterization shows that 
patient tumor is mostly recognized by an acinar growth pattern. Further, the NGS results of the 
patient tumor are positive for EGFR deletion in chromosome 19. This can be detected in 
organoids by EGFR del19 immunofluorescent staining (IF). HE-stain of patient tumors 
compared to the derived organoids shows similar characteristics and growth patterns, with large 




Figure 4.6: Hematoxylin and eosin (HE) stain of patient lung tumor 3 and patient 
derived organoids. a) HE-stain of patient lung tumor 3. b) HE-stain of patient lung tumor 3, zoomed 
insert. c) HE-stain of derived organoids from patient lung tumor 3. d) HE-stain of derived organoids from 
patient lung tumor 3, zoomed insert. Scalebar 100 µm (a and c). Scalebar 50 µm (b and d) 
 
Patient derived tumor organoids from L3 have a large range of different growth patterns. From 
compact structures, to organoids containing one or several small vacuoles, or organoids 
containing large vacuoles. This is shown in Figure 4.7. Both alveolar- and bronchiolar 
differentiated organoids displayed good growth rates. The organoids from L3 are typically 100-
250 µm in diameter, and as seen in Figure 4.7 the more compact organoids are smaller in 
diameter then the lesser compact organoids. Further, the AB-PAS stain of the organoids shows 
that these have a rather efficient production of mucin. Finally, IF stain of the L3 derived 





Figure 4.7: Patient derived lung tumor organoids in culture and with the mucin stain 
AB-PAS. a) Derived organoids from lung tumor patient 3 in culture. b) AB-PAS stain of derived 
organoids from lung tumor patient 3. c) AB-PAS stain of derived organoids from lung tumor patient 3, 
zoomed insert. a) and b) scalebar 100 µm, c) scalebar 50 µm. 
 
 
Figure 4.8: EGFR Immunohistochemistry stain of patient derived organoid. IF stain with 
EGFR antibody on patient derived organoids from L3, DAPI – blue, EGFR - magenta. 
a) Overview of organoid with EGFR stain, scalebar 100 µm. b) Organoid with EGFR stain, zoomed insert, 







4.2.4 Characterization of patient lung tumor 4 and patient derived organoids 
 
The fourth patient lung tumor (L4) received is a squamous cell carcinoma. The patient 
squamous cell carcinoma tumor was large (>7 cm). The initial HE-stain of the patient tumor 
and the derived organoids performed for comparison and characterization shows that the 
resection specimen contains no benign lung tissue. HE-stain also shows that the patient tumor 
is characterized by areas of prominent necrosis, and that the malignant cells are poorly 
differentiated, which makes it easy to separate malignant and benign cells. Furthermore, the 
nuclei are irregular in size as well as in chromatin structure, seen in Figure 4.9. Staining with 
K5/6 antibody of patient tumor performed by the Department of Pathology showed some 
keratinized tumor tissue in the presence of a few pearl formations. Derived organoids display 
very similar growth patterns as tumor of origin, with large and irregular nuclei. Thus, there are 
highly similar characteristics between the organoids and tumor.   
 
 
Figure 4.9: Hematoxylin and eosin (HE) stain of patient lung tumor 4 and patient 
derived organoids. a) HE-stain of patient lung tumor 4. b) HE-stain of patient lung tumor 4, zoomed 
insert. c) HE-stain of derived organoids from patient lung tumor 4. d) HE-stain of derived organoids from 
patient lung tumor 4, zoomed insert. Scalebar 100 µm (a and c). Scalebar 50 µm (b and d) 
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Derived organoids from L4 are only growing in very compact structures with no vacuoles. The 
organoids are typically 100-200 µm in diameter. The organoids have irregular nuclei, like the 
tumor of origin. Further the AB-PAS stain of organoids shows little to no production of mucin, 
seen in Figure 4.10.  
 
 
Figure 4.10: Patient derived lung tumor organoids in culture and with the mucin stain 
AB-PAS. a) Derived organoids from lung tumor patient 4 in culture. b) AB-PAS stain of derived 
organoids from lung tumor patient 4. a) scalebar 100 µm, b) scalebar 50 µm. 
 
 
4.2.5 Characterization of patient lung tumor 5 and patient derived organoids 
 
The fifth patient lung tumor (L5) received is an adenocarcinoma. The initial HE-stain 
performed for comparison and characterization of patient tumor and derived organoids show 
that the tumor is mostly characterized by an acinar growth pattern with biologically aggressive 
characteristics, as seen in Figure 4.11. In particular, the tumor consists of areas of 
macropapillary growth as well as selected areas displaying micropapillary growth pattern, solid 
isolated groups consisting of a few malignant cells. Some infiltrating single tumor cells 
observed. The specimen displays a large degree of nuclear pleomorphism, i.e., the nuclei show 
large variation in size and chromatin structure. Additionally, tumor consists of some areas of 
prominent necrosis. The NGS results from the patient tumor was negative to all tested 









Figure 4.11: Hematoxylin and eosin (HE) stain of patient lung tumor 5 and patient 
derived organoids. a) HE-stain of patient lung tumor 5. b) HE-stain of patient lung tumor 5, zoomed 
insert. c) HE-stain of derived organoids from patient lung tumor 5. d) HE-stain of derived organoids from 
patient lung tumor 5, zoomed insert. Scalebar 100 µm (a and c). Scalebar 50 µm (b and d) 
 
Patient organoids derived from L5 mostly consist of compact structures, some of the organoids 
have smaller vacuoles, this is seen in Figure 4.11. The organoids are usually 50-150 µm in 
diameter. AB-PAS stain of the organoids shows some mucin production, seen in Figure 4.12. 
Some of the organoids seems to resemble the micropapillary growth patterns of the tumor. 
Ultimately, some of the organoids have similar growth patterns as the tumor of origin. Of note, 




Figure 4.12: Patient derived lung tumor organoids in culture and with the mucin stain 
AB-PAS. a) Derived organoids from lung tumor patient 5 in culture. b) AB-PAS stain of derived 
organoids from lung tumor patient 5. c) AB-PAS stain of derived organoids from lung tumor patient 5, 
zoomed insert. a) and b) scalebar 100 µm, c) scalebar 50 µm. 
 
 
4.2.6 Characterization of patient lung tumor 6 and patient derived organoids 
 
The sixth and final patient lung tumor (L6) received is the second squamous cell carcinoma in 
the sample set. Initial HE-stain of patient tumor and derived organoids were performed for 
comparison and characterization (Figure 4.13). The tumor L6 is quite undifferentiated, but still 
more differentiated then the first squamous cell carcinoma tumor received (L4). The tumor 
consists of small necrotic foci and larger areas prominent of palisading necrosis (Figure 4.13 
a). The tumor has a growth pattern characteristic of LUSC with tumor cells in large 
clusters/sheets. Further, a high degree of nuclear pleomorphism is observed; the nuclei are 
irregular in size as well as in chromatin structure with prominent nuclei (these features are not 
sufficient to distinguish squamous cell carcinoma from adenocarcinoma). Cells are rich in light 
eosinophilic cytoplasm. Apoptosis and mitosis are observed, in addition to intercellular bridges, 
which only exists in squamous cell carcinomas. The malignant cells grow in palisade formation, 
resembling a basal formation (Figure 4.14). Finally, single cell keratinization is observed. 





Figure 4.13: Hematoxylin and eosin (HE) stain of patient lung tumor 6 and patient 
derived organoids. a) HE-stain of patient lung tumor 1. b) HE-stain of patient lung tumor 6, zoomed 
insert. c) HE-stain of derived organoids from patient lung tumor 6. d) HE-stain of derived organoids from 
patient lung tumor 6, zoomed insert. Scalebar 100 µm (a and c). Scalebar 50 µm (b and d).  
 
 
Figure 4.14: Hematoxylin and eosin (HE) stain of patient lung tumor. Figure shows an area 
of palisade formation in tumor specimen. Scalebar 100 µm. 
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Derived organoids from L6 tumor display a compact growth pattern, similar to the first 
squamous cell carcinoma derived organoids (L4). Organoid size varies between 50-200 µm in 
diameter. Derived organoids from this specimen consist of large and irregularly sized cell 
nuclei with irregular chromatin, similar to the malignant tissue they derive from. However, 
cytoplasm borders are unclear, which may be due to suboptimal preparation of the specimen. 
Further, some organoids seem to display areas with signs of necrosis, and even the palisade 
formation of the tumor cells in surrounding the necrotic areas, as seen in the malignant tissue 
they derive from (Figure 4.13 d). Mitotic cells are also observed in the organoid specimens. 
AB-PAS stain performed on organoids show none to very little production of mucin, as seen 




Figure 4.15: Patient derived lung tumor organoids in culture and with the mucin stain 
AB-PAS. a) Derived organoids from lung tumor patient 6 in culture. b) AB-PAS stain of derived 
organoids from lung tumor patient 6. c) AB-PAS stain of derived organoids from lung tumor patient 6, 













4.2.7 Ki67 expression in patient derived organoids 
 
For the patient derived organoids with origin from L1-L6, immunofluorescent (IF) staining for 
the proliferation marker Ki67 was performed to assess proliferation in the organoid cultures. 
All organoids express Ki67. The staining shows a heterogenous expression pattern of the 
proliferation marker Ki67 in the different organoids (Figure 4.16).  
 
 
Figure 4.16: Ki67 expression in patient derived lung tumor organoids compared to each 




4.3 The effect of normobaric and hyperbaric oxygen treatment on patient 
derived organoids 
 
Normobaric and hyperbaric oxygen treatment (Norm and HBOT, respectively) were performed 
on patient derived organoids from L1, L2 and L3. The treatment was conducted over five 
consecutive days, and 90-minute treatment each day. Organoids were immediately harvested 
after treatment the last day. IF stain with the proliferation marker Ki67 was performed on the 
two treatment groups compared to control group as shown in Table 4.2 and Fig 4.17. For all 
patient organoid cultures, L1, L2 and L3, most derived organoids were successfully harvested 
from the control group. The least amount of remaining tissue was found in the hyperbaric 
oxygen treatment group, and in normobaric oxygen treatment group an intermediate amount of 
tissue remained after treatment. 
 
Table 4.2 Expression of Ki67 in treated organoids compared to controls.  
Organoid Cell - nuclei Ki67 Pos Nuclei Percentage Ki67 
L1Ctrl 316 33 10,44 % 
L1 Norm 227 2 0,88 % 
L1 HBO 285 49 17,90 % 
L2 Ctrl 312 86 27,56 % 
L2 Norm 507 0 0 % 
L2 HBO 260 62 23,85 % 
L3 Ctrl 537 123 22,91 % 
L3 Norm 506 90 17,79 % 
L3 HBO 82 7 8,54 % 
L3 HBO 2 72 5 6,94 % 
The table shows the expression of proliferation marker Ki67 staining detected in organoids derived from 
organoids treated with normobaric or hyperbaric oxygen therapy (Norm and HBOT, respectively) and control 
group (Ctrl). The table show the total number of nuclei (as determined by DAPI staining), Ki67 positive 
nuclei, and calculated percentage of Ki67 expression in the various groups. One representative section was 
stained and counted for each condition, with the exception of L3 HBO where two sections were analyzed in 




Figure 4.17: Ki67 expression in organoids treated with normobaric- and hyperbaric- 
oxygen. Three different patient derived organoids treated with normobaric- and hyperbaric oxygen 














4.4 Imaging Mass Cytometry  
 
The development of an IMC – panel was initiated in order to be able to perform a deeper 
characterization of the patient derived organoid cultures, as well as deeper investigation of the 
effect of the elevated oxygen treatment. A selection of IMC exported images is presented here 
to illustrate the enormous potential of the technique, in addition to deeper characterization of 
the histoarchitecture, for some of the derived organoids.  
 
4.4.1 Characterization of adenocarcinoma compared to squamous cell carcinoma 
derived organoids  
 
The L3, adenocarcinoma derived organoids, of both alveolar and bronchiolar differentiation, 
showed expression of collagen type I, laminin, histone H3, vimentin, E-cadherin, CK7, K8/18, 
TRP63 as well as Ki67, seen in Figure 4.18 and 4.19.  
 
 
Figure 4.18: L3 P1 Alveolar differentiated patient derived organoids, imaging mass 
cytometry exported images. a) Iridium – blue, Collagen type I – red, Laminin – Lime. b) Histone H3 – 
blue, Vimentin – red, E-cadherin – lime. c) Iridium – blue, Vimentin – red, E-cadherin – Lime, Ki67 – white. 








Figure 4.19: L3 P1 Bronchiolar differentiated patient derived organoids, imaging mass 
cytometry exported images. a) Histone H3 – blue, Collagen type I – red, Laminin – Lime. b) Histone 
H3 – blue, Vimentin – red, E-cadherin – lime, Ki67 – white. c) Histone H3 – blue, CK7 – red, K8/18 – Lime, 
TRP63 – white. Scalebar: 100 µm.   
 
The L4, squamous cell carcinoma derived organoids, bronchiolar differentiated, show 
expression of histone H3, E-cadherin, Ki67, TRP63, and a low expression of K8/18. The 
organoid structure does not show expression of collagen type I, laminin, vimentin nor CK7. 
Seen in Figure 4.20.  
 
 
Figure 4.20: L4 P0 Bronchiolar differentiated patient derived organoids, imaging mass 
cytometry exported images: a) Histone H3 – blue, Collagen type I – red, Laminin – Lime. b) Histone 
H3 – blue, Vimentin – red, E-cadherin – lime, Ki67 – white. c) Histone H3 – blue, CK7 – red, K8/18 – Lime, 
TRP63 – white. Scalebar: 100 µm  
 
Phenograph clusters were made from the three samples. Further, a heatmap was generated out 
of the cluster. In the heatmap, the clusters are represented in rows, and the selected markers in 
columns. Data are displayed on a scale from zero (blue) to one (yellow). In the tSNE plot, each 
cluster is highlighted in a different color. Results in Figure 4.20.   
 56 
 
Figure 4.20: Phenograph heatmap and tSNE visualization of clusters from L3 P1, both 
alveolar and bronchiolar differentiated, and L4 organoids. a) Phenograph heatmap. b) tSNE 


















5. Discussion  
 
5.1 Methodological considerations 
 
5.1.1 Three-dimensional organoid model 
 
3D patient derived organoids have recently emerged as a unique and robust tool for screening 
of therapeutic efficiency and toxicity testing. These patient derived in vitro organoid models 
have several advantages compared to the two-dimensional cultures and animal models. First, a 
patient derived organoid model will give better representation of the tumor heterogeneity than 
other in vitro models as they are derived from different patients and multiple cells as opposed 
one single cell, that many cell lines used for in vitro experiments derive from. Furthermore, 
they will resemble human biology and tissue functionality better than the in vivo animal models, 
since they maintain the histoarchitecture as well as genetic mutations of the tumor of origin 
(43). Thus, organoid models represent a particularly good starting point for personalized 
treatment research.  Finally, the method is relatively quick, less expensive, and ethically 
superior to using animals. However, the patient derived three-dimensional models are not 
perfect, as they are not vascularized and lack certain cell types (e.g., immune cells) that 
normally appear in the tumor microenvironment in vivo (44).  
 
 
5.1.2 Three-dimensional organoid model in Imaging Mass Cytometry 
 
In order to be able to apply this 3D organoid model for techniques such as IMC and other 
tissue staining techniques, the harvesting method have been optimized as a part of this master 
project. We needed to optimize the protocol for embedding the organoids to obtain good 
results compatible with the downstream histology and IMC analyses. In the start we had 
problems with the harvesting and was able to only get a few good organoids on each section. 
To solve this problem centrifuging and heating of equipment in the agar embedding process 
was added. The optimization gave in general more organoid tissue per section and made it 
possible to get good and representative staining results. Following our studies, we conclude 
that the organoid cultures are compatible with the IMC technology.  
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5.1.3 Elevated oxygen treatment 
 
The temperature in the hyperbaric chamber was reached by heating the chamber in advance of 
the treatment. An automatic electric heater, calibrated to 37ºC, would of course give a more 
stable and precise temperature, however electrical apparatus within the oxygen chamber will 
pose a fire hazard and could therefore not be applied. Thus, there was a slight temperature 
decrease during the treatment period, although not so much that we believe it would influence 
the results to any great extent. 
 
The number of organoids harvested in the treatment groups were low, probably due to an 
hyperoxic inhibition of growth. Thus, usage of IncuCyte platform for quantification to monitor 
alterations in organoid numbers and size in order to be able to conclude about the treatment 
effect should be added in the next run of experiments. Furthermore, to be able to harvest enough 
organoids for downstream analyses, such as a large IMC experiment, the solution could be to 
have more replicates in the treated groups.  
 
 
5.1.4 Imaging mass cytometry 
 
Imaging mass cytometry (IMC) is a novel technique.  It is the world’s first and most proven 
high-multiplex imaging and single-cell protein analysis (45). IMC allows labeling of tissue 
sections with up to 40 heavy metal-conjugated antibodies simultaneously (46). The available 
Hyperion/Helios (Fluidigm platform) Imaging System at UiB, made it possible to apply IMC 
as a tool for deeper characterization of the patient derived lung tumor organoid model in this 
project. This technology gave us the opportunity to gather information on the tissue architecture 
of the derived organoids, as well as the cellular morphology (47). This preliminary work has 
shown that the IMC technology is also a particularly well suited in combination with organoid 
models. However, the cost of performing an IMC project is very high, and it is also highly time-
consuming technique with respect to panel design and optimalization and downstream analyses.  
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5.1.4.1 Imaging Mass Cytometry workflow 
 
In an IMC experiment, solid tissue samples, either FFPE or frozen, is sectioned and mounted 
on glass slides, deparaffinized and rehydrated. We used FFPE sections, which preserves 
excellent tissue morphology compared to the frozen sections. This can easily be incorporated 
into routine tissue processing, and storage. The sample sections were subjected to antigen 
retrieval to expose tissue antigens. These were then blocked with serum proteins to reduce 
unspecific binding before labeling with a heavy metal conjugated antibody cocktail. Followed 
by labeling with a heavy metal DNA intercalator (Iridium). After the labeling workflow, 
Regions of Interest (ROIs) of labeled sections were selected. The IMC-system measures the 
levels of heavy metal ablated segments of the tissue (1 µm2) and correspond each of the heavy 
metal tags to individual pixel intensities in the selected ROIs. Further the analyzed tissue was 
subjected to cell segmentation by using the DNA intercalator label for identification of nuclei. 
The cell segmentation is highly dependent on good signal and good titration, and we could 
observe that the segmentation got better for each test run. For the cell segmentation, we decided 
to supplement the DNA intercalator Iridium label with the nuclear marker, Histone H3, due to 
a very good signal. This alteration of the protocol improved the cell segmentation. Finally, the 
cell masks were analyzed by exporting and importing images to downstream analyzing tools.  
 
The staining procedure for an IMC experiment is rather straight forward once one have gained 
experience with the complex workflow. However, there are some possible “traps” throughout 
workflow that we tried to avoid. It is important to use fresh xylene for the dewaxing, in addition, 
washing steps should be performed by using dedicated containers, never washed in detergent, 
to avoid barium contamination.  
 
 
5.1.4.2 Imaging Mass Cytometry panel development 
 
In the development of an IMC panel, a huge number of factors must be taken into consideration. 
First, we needed to consider which antibodies were relevant for the chosen tissue of interest, 
namely NSCLC tissues. Furthermore, the choice of the corresponding heavy metal channels for 
each antibody. We had to consider the in-house antibody inventory. We decided to use the in-
house antibody inventory as a foundation for the panel. A growing selection of commercially 
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available pre-conjugated antibodies are available in selected channels. Some antibodies were 
purchased, and some central markers were conjugated by us in-house. Of note, the success rates 
vary for the in-house conjugation; however, they are great for cost savings and the success rate 
is expected to increase with experience. Furthermore, some of the available channels are more 
sensitive, so markers with low abundance were preferably placed here (48).   
 
In this project, central markers for hypoxia, such as HIF1 alpha and VEGFA was prioritized, 
together with EMT markers and lineage specific cell markers. ECM markers, such as laminin 
and collagen type I were incorporated into the panel. Two separate panels were designed. The 
first panel for the original patient derived organoid model (Sachs et al.), and a second panel 
including immune cell markers for use in combination with the explant culture method. The 
second panel can be used with an organoid model in development, where immune and other 
stromal cells will be preserved in the tissue.  
 
The strategy for the development of the IMC panel in thesis was to; 1) test of current in-house 
CyTOF and Hyperion validated antibodies, 2) acquire, and test new Hyperion validated 
antibodies, and 3) conjugate the remaining panel specific in-house markers. Validation of all 
antibodies was conducted with the use of positive controls we had generated for this purpose.  
 
The development of the IMC panel was extremely time consuming. Especially the validation 
and titration of the desired antibodies. First and foremost, the antibodies were validated by 
staining the tissue of interest and compared it to a positive control tissue. Although markers 
could be positive in our tissue even though the signal might be much higher in the positive 
control, this was considered for the titration. These test runs might have to be repeated up to 
several times for an accurate validation and titration. Three test runs of a highly multiplexed 
antibody-panel were performed for validation and titration, before the main experiment. 
Although, even more runs should be performed to get sufficient validation and optimal titration 
for all included antibodies.   









5.2 Result discussion 
 
5.2.1 Development of human airway organoid 
 
Establishment of a patient derived lung tumor organoid model is an important and necessary 
step for a better understanding of cancer development and progression, as well as a model for 
testing the efficacy of experimental therapies.   
 
In the culturing, two defined serum free differentiation media were used, bronchiolar- and 
alveolar medium. The difference between these is the addition of CHIR, a Wnt activator, in the 
alveolar differentiation medium. This addition is necessary because the alveolar-type cells 
poorly proliferate in ex vivo conditions. The Wnt activator have previously shown to  promote 
alveolar differentiation (49). Culture of organoids in both differentiation mediums were 
successful, although, in general a better growth was observed in the bronchiolar differentiated 
medium. Furthermore, we observed a variation in survival time when compared to organoids 
grown in the two different media. For some of the derived organoids, the bronchiolar 
differentiation medium gave longer survival, however others had better survival in the alveolar 
differentiation medium.  This could be due to the preference of the organoid initiating cells.  
Alveolar cells have been shown to display lower proliferation, compared to bronchiolar cells. 
Alveolar cells have also shown to have loss of function over time (50). Additionally, growth 
rates vary between organoids derived from the different patient tumors, and this was as expected 
based on characterization of them.   
 
Only stage I and II tumor resection were supposed to be received for the establishment of a 
patient derived organoid model. This is because surgery is a standard treatment strategy for 
stage I and II patients. For stage III and IV patients, surgery is not a standard recommendation 
(14, 15). However, due to margin of error of clinical staging some patients get a new stage 






5.2.2 Characterization of organoids compared to tumor of origin.  
 
One of the objectives of this thesis was to establish patient derived organoids originating from 
a variation of malignant phenotypes to examine differences in success of establishment as well 
as the histoarchitecture.  
 
Adenocarcinomas are classified by five different predominant patterns, lepidic-, papillary-, 
acinar-, micropapillary- and solid adenocarcinoma (16). Three of these is a focus of this thesis. 
Lepidic predominant adenocarcinomas consists of atypical type II pneumocytes or Clara cells 
with malignant growth along normal structures, such as the alveoli (51). Papillary 
adenocarcinoma are defined as adenocarcinomas with over 75% of papillary structures 
supported by fibrovascular cores replacing the alveolar architecture (52). Acinar 
adenocarcinomas are characterized with round to oval glandular structures with luminal spaces 
surrounded by malignant cells (53). The squamous cell carcinomas are divided into 
keratinizing- and non-keratinizing squamous cell carcinoma. Typical markers of this 
malignancy are p40, CK5, CK6 and p63 (TRP63) (16).  
 
In diagnosis of NSCLC, growth patterns and characteristics are assessed. To be able to separate 
adenocarcinomas from squamous cell carcinomas, the pathologist often applies AB-PAS 
histochemistry or IHC-P stain of tumor specimen tissue sections due to similar growth patterns. 
The two are often inseparable assessed from nuclear pleomorphism. Therefore, the AB-PAS 
stain of derived organoids was performed, to ease the comparison between organoids and 
patient tumor. As expected, organoids derived from adenocarcinomas displayed a higher 
secretion of mucin in the AB-PAS stains compared to the squamous cell carcinoma derived 
organoids. Also, the cell of origin which for adenocarcinomas has not been firmly established. 
However, candidates believed to be the cell of origin is Clara cells and type II pneumocytes 
(54). The type II pneumocytes are mucin secreting. Furthermore, the lack of mucin secretion in 
the squamous cell carcinoma organoid, might be a sign of lack of normal type II pneumocytes, 
and as such serves as an argument that the protocol is well suited to preserve malignant cells 
on the expense of normal non-malignant cells in culture. Of note, some research has shown 
similar patterns of mucin secretion in both adenocarcinomas and squamous cell carcinomas 
(55), and thus mucin secretion alone cannot be applied to discriminate between the two. 
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Antibody staining could be used for deeper investigation of mucin secretion. Department of 
Pathology at Haukeland University hospital uses two double stains for separation between 
adenocarcinoma and squamous cell carcinoma in the clinic. These are; TTF1 and NepsinA for 
adenocarcinoma and p40 and K5/6 for squamous cell carcinoma. These were performed when 
the pathologist deemed it necessary.  
 
The addition of the IHC-P staining would also be useful to see if organoids preserve the 
typically characteristics of tumor derived from. These stains should be done, for further 
investigation of organoids characteristics and evaluation of their heterogeneity in cultures.  
 
Patient derived organoids from adenocarcinomas have in general less compact structure 
compared to the squamous cell carcinoma derived organoids, resembling the in vivo growth 
pattern. Organoid size seems to vary between the tumor of origin rather than between 
adenocarcinoma and squamous cell carcinoma. Though, the size of the organoids rarely 
exceeded 200 µm in diameter in our experiment. For the less aggressive lung adenocarcinomas, 
this could be due to the limitation of alveoli size, which have an average size around 200 µm 
in diameter (56). For others the availability of oxygen and nutrients in the compact structures 
could serve to limit their growth. Prominent characteristics from patient tumor was preserved 
in derived organoids, such as the palisade formation in L6 (Figure 4.13 and 4.14). Organoids 
derived from tumors with prominent necrosis seems to have preserved necrotic areas (Figure 
4.13), and this could be particularly useful for future studies of hypoxic microenvironment and 
hyperoxia as a therapeutic avenue. Furthermore, all derived organoids have relatively high 
expression of Ki67 as anticipated by the literature (57).  
 
Finally, next generation sequencing (NGS) was performed on all adenocarcinomas, to 
investigate positive incidence of mutations. The respective derived organoids were stained with 
antibody. Unfortunately for the project, only one of the received patient adenocarcinoma tumors 
(L3) was positive for genetic alterations. The NGS of L3 tumor detected EGFR mutation in 
chromosome 19. EGFR mutation is the most common genetic mutation in NSCLC, with around 
10% positive cases in Norway (58). Immunofluorescent antibody staining to detect EGFR 
chromosome 19 deletion were performed. The EGFR chromosome 19 deletion found by NGS 
in the patient tumor were confirmed in the organoids by positive staining (Figure 4.8) This 
result confirms that the patient derived organoids preserved also the genetic aberrations from 
the tumors they derive from, as expected according to the literature (43). 
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A challenge with the patient derived tumor models is the preservation of the malignant cells. 
The HE-stains indicates that, for most of the derived organoids, the cancer cells are preserved 
on the expense of normal cells in the culture. However, some of the L5 organoids looked more 
like normal lung organoids, while most resembles the micropapillary features of the tumor of 
origin. Ultimately, preservation of malignant cells in organoids on the expense of normal cells 
needs further investigation. One strategy could be to use the NGS results. Positive findings in 
the targeted NGS could make exclusion of growth factors in the medium recipe possible and 
thus promote growth of the cancer cells only, in the organoid cultures.  
 
Thus, in conclusion we have shown that the characteristics of different PDO cultures differ 
from patient to patient, as one would expect, due to heterogeneity and lung cancer subtype. 
However, most importantly, the PDO´s show largely similar characteristics to the lung tumor 
of origin. This attribute makes patient 3D organoids applicable for clarification of treatment 
strategy for the individual patient, as shown by several researchers (59-61).  
 
 
5.2.3 The effect of normobaric and hyperbaric oxygen treatment on patient 
derived organoids 
 
Since hypoxia is a key factor in tumor growth and progression, our aim was also to evaluate the 
effect of hyperoxia (“the flip of the coin”) on lung tumors. To the best of our knowledge, this 
has not been done before.  
 
Thus, elevated oxygen treatment, normobaric and hyperbaric, was performed on three of the 
organoid cultures, namely L1, L2, and L3. 
 
Of note, we observed less organoids in the treated groups compared to control group which 
might indicate a growth inhibition due to the elevated oxygen. This correlates to in vivo studies 
on breast cancer after normobaric and hyperbaric oxygen treatment (62, 63). Ki67, a cell 
proliferation marker expressed in all active cell cycling phases, but not in the inactive phase 
(64), was stained by IF. This cell cycle phase- marker is associated with poor prognosis and 
cancer proliferation (65). Furthermore, Ki67 is induced by hypoxia, and has previously been 
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found to have high expression in hypoxic conditions (66, 67). Thus, we elucidated if enhanced 
oxygen would reduce this marker. However, only the normobaric treated showed significant 
reduction in Ki67. The hyperbaric treated however showed various results. Especially, in L2, 
where the organoids treated with normobaric oxygen show no expression of the proliferation 
marker Ki67. We cannot rule out that this could be due to staining error. Only L3 showed 
reduction of Ki67 staining under HBOT. However, the variable results could also reflect inter-
person variability, and these experiments need to be performed again in order to be able to draw 
any firm conclusions. In the interest of time, since establishing the organoid cultures and 
embedding and sectioning them is a time-consuming process, we only got the opportunity to 
evaluate the effect of normobaric and hyperbaric oxygen therapy in L1, L2, and L3. From what 
we later learnt from histological examination, these were not the most hypoxic specimens out 
of the six tumors we established cultures from, and thus not the ones most likely to benefit from 
the normobaric and hyperbaric oxygen therapy. Thus, when repeating these experiments, we 
will use the organoids that show most severe hypoxia in patient tissues as well as organoid 
tissues, as we hypothesize that these will benefit most from the elevated oxygen therapy.  
Hyperbaric oxygen therapy could also be evaluated as personal treatment, and we conclude that 
the organoid models could be a suitable platform to test the efficacy of treatment and aid in the 














5.2.4 Imaging Mass Cytometry Results 
 
We wanted to further investigate the histoarchitecture of the patient derived organoids, by 
conducting an experiment with the single cell high dimensional analysis technique, imaging 
mass cytometry.  
 
The results show that there are some differences in the cellular compositions of organoids 
derived from adenocarcinomas compared to from squamous cell carcinomas.  
 
Firstly, CK7 are only expressed in the adenocarcinoma derived organoid, this was expected. 
CK7 are expressed in almost all adenocarcinoma cases, and rarely expressed in squamous cell 
carcinomas (68). CK7 are often used as a marker to distinguish the two types (69).  
 
Secondly, two markers for EMP were included in the IMC results, these were, E-cadherin and 
vimentin. However, both E-cadherin and vimentin are expressed in the adenocarcinoma derived 
organoids, while only E-cadherin and not vimentin are expressed in the squamous cell 
carcinoma derived organoids. Both of these markers are expected to be expressed in both types. 















Aim 1: Establish an organoid model from human non-small cell lung cancer resection 
specimens. 
 
We managed to establish patient derived organoid cultures from a variety of different subtypes 
of NSCLC, four lung adenocarcinomas and two lung squamous cell carcinomas. We conclude 
that this was a relatively manageable procedure with a 100% success rate in this project.  
 
With the added advantage of two individual differentiation media, the model is well suited for 
a wide range of future research purposes. Additionally, the procedure can be applicable for 
culturing of both normal and malignant lung tissue organoids from the same patient which is a 
great advantage for future application in cancer research e.g., for drug efficacy and toxicity 
testing of novel anti-cancer compounds and treatment modalities. 
 
 
Aim 2: Characterize the histoarchitecture and cellular composition of the organoids 
compared to the malignant tumors they derive from. 
 
The patient derived organoids, form the different types of NSCLC, largely resemble the tumor 
of origin. The organoid cultures were determined to be heterogenous as expected due to the 
different types of NSCLC. And we were able to show that the 3D derived organoids in culture 
have preserved the histoarchitecture, and genetic mutations from the tumor they derived from 
were preserved. Additionally, the model was proven to obtain the functional ability of 
adenocarcinomas for mucin secretion, as determined by AB-PAS histochemistry.  
 
We conclude that similar growth characteristics and histology between derived organoids and 






Aim 3: Explore the effect of normobaric and hyperbaric oxygen treatment on cancer cell 
proliferation and phenotype, as well as ECM composition. 
 
There seems to be less success in harvesting of organoids in the elevated oxygen treatment 
groups. Thus, these experiments need to be repeated with readouts on organoid number and 
size, as well as a live-dead marker included. 
 
Our results indicate that elevated oxygen treatment influenced the cancer cell proliferation, as 
evidenced by less tissue. The normobaric oxygen treatment downregulates the proliferation 
marker Ki67, as one might expect, while the hyperbaric oxygen treatment showed variable 
results. Thus, these experiments should be repeated, and the most hypoxic organoid cultures 
should also be tested.  
 
Thus, due to the preliminary nature of the results, we cannot conclude firmly whether or not 
elevated oxygen therapy is a promising therapeutic alternative for NSCLC, but our results 
support future exploration of this experimental therapy in the NSCLC organoid model 














6. Future Perspectives 
 
Taking the severity of lung cancer into consideration it is an important step to develop models 
more representative to the clinical cancer. This is important both for understanding the 
malignancies and the progressive tumor development and for the search for new therapeutic 
strategies.   
 
The 3D patient derived organoid model established in this thesis show promising results with 
respect to preservation of histoarchitecture, functional characteristics and preservation of 
genetic mutations from patient tumors. Furthermore, we have shown that such a model is well 
suited in combination with single cell high dimension analysis, and especially IMC which also 
gives detailed spatial information. To this day, not enough is known regarding the detailed 
impact of hypoxia on the tumor microenvironment. This thesis has shown that the organoid 
model is a good starting point on future research on hypoxias effect on the tumor 
microenvironment, to get a better understanding of the complex communication between cancer 
cells and stromal cells. The combination of these two techniques is well suited for research in 
the area of precision medicine.  
 
First of all, further analysis of the already acquired IMC data is to be performed. Due to 
unplanned service of the Hyperion imaging system, we did not have the time to complete the 
analyzation. Validation of HIF1 alpha in addition to VEGFA, for experiments on treated 
organoids could give a better conclusion on the effect of the elevated oxygen treatment.  
Furthermore, the addition of the antibodies used at the Department of pathology; p40 and K5/6 
– adenocarcinoma and TTF1 and NepsinA – squamous cell carcinoma to the IMC panel would 
be an ideal next step for the panel design. In addition to the hypoxia markers in our panel, we 
want to add the hypoxia probe, pimonidazole, a 2-nitroimidazole, which is directly correlated 
with the level of hypoxia (71).  
 
Our group have also started the development of a patient derived organoid model with the 
preservation of immune cells. A name for this new model is not yet decided, but it is either 
going to be called “organotypic spheroids” or “patient derived explant cultures”. The longevity 
of a such a model is short compared to this model, but it could be around two weeks to one 
month before the decrease of the immune cells. The addition of this new organoid model with 
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the preservation of immune as well as other stromal cells are also interesting for future studies, 
even though these have a shorter longevity compared to the model developed in this project 
where mainly malignant epithelial cells are preserved and expanded. However, the preservation 
of these immune and stromal cell will be even more representative of the cancer in situ with 
components of the complex tumor immune microenvironment present. Thus, this “patient 
derived explant culture” model is well suited for the elevated oxygen treatment model and will 
complement the model established here very well. Possible complications with the hyperbaric 
oxygen treatment on lung cancer patients, makes it more reasonable to introduce the normobaric 
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